| Pharmaceutical Information |
| Drug Name |
Fesoterodine |
| Drug ID |
BADD_D00891 |
| Description |
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. |
| Indications and Usage |
For the treatment of overactive bladder (with symptoms of urinary frequency, urgency, or urge incontinence). |
| Marketing Status |
approved |
| ATC Code |
G04BD11 |
| DrugBank ID |
DB06702
|
| KEGG ID |
D07226
|
| MeSH ID |
C526675
|
| PubChem ID |
6918558
|
| TTD Drug ID |
D00BLL
|
| NDC Product Code |
47621-025; 50370-0047 |
| UNII |
621G617227
|
| Synonyms |
fesoterodine | toviaz | fesoterodine fumarate |
|
| Chemical Information |
| Molecular Formula |
C26H37NO3 |
| CAS Registry Number |
286930-02-7 |
| SMILES |
CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=C2 |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
